Table 2.

Drugs under Clinical Development.

Drug	Chemical Class	Phase	Mechanism of Action
	diarylquinoline	Pre-phase 1	Inhibits ATP synthase and inhibits respiration
	spectinamide	Pre-phase 1	Binds to the ribosome and inhibits protein synthesis
	benzothiazinone	1	Forms a covalent adduct with DprE1 and inhibits arabinogalactan synthesis
	benzothiazinone	1	Forms a covalent adduct with DprE1 and inhibits arabinogalactan synthesis
	azaindole	1	Binds to DprE1 and inhibits arabinogalactan synthesis
OPC-167832*	dihydrocarbostyril	1	Binds to DprE1 and inhibits
			arabinogalactan synthesis
	imidazopyridine	1/2	Binds to the QcrB subunit of cytochrome bc1 and inhibits respiration
	oxazolidinone	1/2	Binds to the ribosome and inhibits protein synthesis
	oxazolidinone	2	Binds to the ribosome and inhibits protein synthesis
	oxazolidinone	2	Binds to the ribosome and inhibits protein synthesis
	ethylenediamine	2	Binds to MmpL3 and inhibits cell wall synthesis
	fluoroquinolone	2	Binds to DNA gyrase and inhibits DNA replication
	nitrothiazole	2	Disrupts the membrane potential and pH homeostasis
	diarylquinoline	3	Binds to ATP synthase and inhibits respiration
	nitroimidazole	3	Blocks synthesis of mycolic acids and forms NO
	nitroimidazole	3	Blocks synthesis of mycolic acids and forms NO.
	riminophenazine	3	Reduced by NADH dehydrogenase II and subsequently forms reactive oxygen species

^*The general structure of OPC-167832 shown here was taken from the US patent No. US2017/0253576 A1.

More compounds in clinical development can be found at www.newtbdrugs.org